黄葵胶囊联合氯沙坦治疗肾移植术后蛋白尿的临床观察

Clinical observation of effect on Huangkui Capsule combined with Losartan in treating proteinuria after renal transplantation

目的探讨黄葵胶囊联合氯沙坦治疗肾移植术后蛋白尿的临床疗效。方法接受尸体肾移植、术后时间达半年以上、24 h尿蛋白定量≥300 mg的患者80例,将其随机分成治疗组(40例)和对照组(40例)。治疗组给予黄葵胶囊5粒,每日3次,口服;同时服用氯沙坦80 mg,每日1次,口服。对照组给予氯沙坦80 mg,每日1次,口服。连续用药8周,在用药前及用药8周后分别测定24 h尿蛋白定量、血白蛋白、肾功能,并比较组间差异和组内差异,同时评价临床疗效。结果治疗组总有效率明显优于对照组,差异有统计学意义(P<0.05);连续用药8周后,治疗组尿白蛋白、血清白蛋白测定结果与对照组比较,差异有统计学意义(P<0.05);治疗组组内不同时间所有测定结果比较差异有统计学意义(均P<0.05)。结论黄葵胶囊联合氯沙坦治疗肾移植术后蛋白尿安全有效,值得临床推广使用。

Objective To investigate the clinical effect of Huangkui Capsule combined with Losartan in treating proteinuria after renal transplantation.Methods 80 patients who accepted cadaveric renal transplantation more than six months and whose urinary protein ≥300 mg were randomly divided into treatment group（40 cases） and control group（40 cases）.Treatment group was given 5 pills of Huangkui Capsules,3 times a day and Losartan 50 mg,once a day.While control group was given only Losartan 50 mg,once a day.The course of treatment was 8 weeks.24 h urinary protein,albumin,renal function,levels were measured before and after treatment,differences within groups and between groups were compared and clinical effect were evaluated.Results The total effective rate of treatment group was better than control group,there were statistically significant differences（P〈 0.05）;after 8 weeks,urinary albumin and serum albumin in treatment group dropped significantly,there were statistically significant differences（P〈 0.05） when compared with control group.All results measured in different time within treatment group were statistically significant different（all P〈 0.05）.Conclusion It is safe and effective of the combined treatment of Huangkui Capsule and Losartan in proteinuria after renal transplantation and worthy of clinical use.